ScholarIQanswers from OpenAlex & ORCID
Alexander C. J. van Akkooi
ResearcherPublications, citations & collaboration network
Alexander C. J. van Akkooi is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Alexander C. J. van Akkooi have?
ScholarIQindexed works
Alexander C. J. van Akkooi has 475 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Alexander C. J. van Akkooi have?
ScholarIQcitation count
Alexander C. J. van Akkooi has 19,243 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Alexander C. J. van Akkooi?
ScholarIQh-index
Alexander C. J. van Akkooi has an h-index of 55 in OpenAlex.
What is the i10-index of Alexander C. J. van Akkooi?
ScholarIQi10-index
Alexander C. J. van Akkooi has an i10-index of 187 in OpenAlex.
What is the ORCID of Alexander C. J. van Akkooi?
ScholarIQorcid
The ORCID for Alexander C. J. van Akkooi is on the source record.
What is the OpenAlex record for Alexander C. J. van Akkooi?
ScholarIQopenalex
The OpenAlex for Alexander C. J. van Akkooi is on the source record.
What are the most-cited papers on Alexander C. J. van Akkooi?
ScholarIQmost cited works
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Mikhail Lichinitser, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Michele Maio, Alfonsus Johannes Maria van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul Lorigan, Nageatte Ibrahim, Sandrine Marréaud, Alexander C. J. van Akkooi, Stefan Suciu, Caroline Robert
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma
Maartje W. Rohaan, Troels Holz Borch, Joost H. van den Berg, Özcan Met, Rob Kessels, Marnix H. Geukes Foppen, Joachim Stoltenborg Granhøj, Bastiaan Nuijen, Cynthia M. Nijenhuis, Inge Jedema, Maaike van Zon, Saskia Scheij, Jos H. Beijnen, Marten Hansen, Carlijn Voermans, I.M. Noringriis, Tine J. Monberg, Rikke Boedker Holmstroem, Lidwina D.V. Wever, M. van Dijk, Lindsay G. Grijpink-Ongering, Ludy H.M. Valkenet, A. Torres Acosta, Matthias Karger, Jessica S.W. Borgers, Renske M.T. ten Ham, Valesca P. Retèl, Wim H. van Harten, Ferry Lalezari, Harm van Tinteren, Astrid A.M. van der Veldt, Geke A.P. Hospers, Marion A. M. Stevense‐den Boer, Karijn P.M. Suijkerbuijk, Maureen J.B. Aarts, Djura Piersma, Alfons J.M. van den Eertwegh, Jan‐Willem B. de Groot, Gerard Vreugdenhil, Ellen Kapiteijn, Marye J. Boers‐Sonderen, W. Edward Fiets, Franchette W.P.J. van den Berkmortel, Eva Ellebæk, Lisbet Rosenkrantz Hölmich, Alexander C. J. van Akkooi, Winan J. van Houdt, Michel W.J.M. Wouters, Johannes V. van Thienen, Christian U. Blank, A. Meerveld-Eggink, Sebastian Klobuch, Sofie Wilgenhof, Ton N. Schumacher, Marco Donia, Inge Marie Svane, John B.A.G. Haanen
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
Alexander Eggermont, Christian U. Blank, Mario Mandalà, Georgina V Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Anna Maria Di Giacomo, Alfons J.M. van den Eertwegh, Jean‐Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul Lorigan, Alexander C. J. van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marréaud, Michal Kiciński, Stefan Suciu, Caroline Robert, Alex Menzies, Thierry Lesimple, Michele Maio, Gerald P. Linette, Michael P. Brown, Peter Hersey, Inge Marie Svane, Laurent Mortier, Jacob Schachter, Catherine Barrow, Ragini R. Kudchadkar, Xinni Song, Caroline Dutriaux, Pietro Quaglino, Friedegund Meier, Paola Queirolo, Daniil Stroyakovskiy, Lars Bastholt, B. Guillot, Claus Garbe, Pablo L. Ortiz‐Romero, Florent Grange, Peter Mohr, Alain P. Algazi, Oliver Bechter, Micaela Hernberg, Jean‐Philippe Arnault, Philippe Saïag, Carmen Loquai, Frank Meiß, Jan‐Christoph Simon, Gil Bar‐Sela, Vanna Chiarion‐Sileni, Bernard M. Fitzharris, Mike McCrystal, Phillip Parente, Jean‐François Baurain, P. Combemale, Célèste Lebbé, Axel Hauschild, Naoya Yamazaki, Reinhard Dummer, Mohammed Milhem, Marcin Dzienis, John Walker, L. Geoffrois, M.‐T. Leccia, Lutz Kretschmer, Daniel Hendler, Michal Lotem, Andrzej Maćkiewicz, Lidija Kandolf Sekulović, Elaine Dunwoodie, Christoph Höeller, L. Machet, Jessica C. Hassel, Geke A.P. Hospers, Maria-Jose Passos, Max Levin, Martin Fehr, Philippa Corrie, Ashita Waterston, Sigrun Hallmeyer, Henrik Schmidt, V. Descamps, J.‐P. Lacour, Carola Berking, Felix Kiecker, Pier Francesco Ferrucci
Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative?
Alexander C. J. van Akkooi, Johannes H. W. de Wilt, Cornelis Verhoef, Paul Schmitz, A.N. van Geel, Alexander M.M. Eggermont, Mike Kliffen
Sentinel Node Tumor Burden According to the Rotterdam Criteria Is the Most Important Prognostic Factor for Survival in Melanoma Patients
Alexander C. J. van Akkooi, Zbigniew Nowecki, Christiane Voit, Gregor Schäfer-Hesterberg, Wanda Michej, Johannes H. W. de Wilt, Piotr Rutkowski, Cornelis Verhoef, Alexander M.M. Eggermont